NGL Fine-Chem Ltd
Company Profile
Business description
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
Contact
301, E Square, Subhash Road
Vile Parle (East)
MumbaiMH400057
INDT: +91 2240842222
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2026
Employees
523
Stocks News & Analysis
stocks
Anglo American strikes deal to create a new copper giant
stocks
The ‘other’ AI chip behemoth that might just be getting started
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,071.40 | 9.10 | -0.10% |
CAC 40 | 7,820.09 | 58.77 | 0.76% |
DAX 40 | 23,649.45 | 16.50 | 0.07% |
Dow JONES (US) | 45,490.92 | 220.42 | -0.48% |
FTSE 100 | 9,263.51 | 38.12 | 0.41% |
HKSE | 26,086.32 | 113.94 | -0.43% |
NASDAQ | 21,886.06 | 6.57 | 0.03% |
Nikkei 225 | 44,372.50 | 534.83 | 1.22% |
NZX 50 Index | 13,229.15 | 47.09 | -0.35% |
S&P 500 | 6,532.04 | 19.43 | 0.30% |
S&P/ASX 200 | 8,805.00 | 8.80 | -0.10% |
SSE Composite Index | 3,875.31 | 63.09 | 1.65% |